Over the past five years, the stock has recorded a negative one-day return in 65% of cases, with a median decline of -2.4% ...

We recently compiled a list of Billionaire Prem Watsa’s 10 Stock Picks With Highest Potential. In this article, we are going ...

Fintel reports that on April 22, 2025, Cantor Fitzgerald initiated coverage of Merck (NYSE:MRK) with a Neutral recommendation ...

Merck & Company (MRK – Research Report) received a Hold rating and an $85.00 price target from Cantor Fitzgerald analyst Carter Gould ...

When Merck reports first-quarter earnings, investors are likely to focus on the sales of its blockbuster oncology medicine, Keytruda.

Merck is growing pharma sales and expanding margins, led by strong KEYTRUDA performance and cost discipline. Read more about ...

Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector. UBS analyst ...

PM closed at $163.21 on Friday, earning the tobacco company a valuation of $254 billion. The stock is up 35.6% year-to-date in 2025, ranking it towards the top of the S&P 500 index.

Merck, Black Hills, and Virtus Investment Partners are good choices for investors seeking reliable passive income. Their ...

We recently published a list of 10 Best Pharma Stocks to Buy for Long Term Growth. In this article, we are going to take a ...

NEW YORK, NY / ACCESS Newswire / April 14, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...

Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Merck & Co., Inc. (NYSE: MRK) between ...